{"analyses":[{"ciLowerLimit":"3.72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.42","groupDescription":"For the analysis of susceptibility to infection, the time to next infection was examined using the Andersen-Gill model. This model is an extension to the proportional hazard model (Cox model) for time to recurrent event analysis. The null hypothesis is that the GLAD-Score has no effect on susceptibility to infection.","groupIds":["OG000","OG002"],"nonInferiorityComment":"To estimate the relevance of guideline adherent treatment (GLAD) for the susceptibility to infection, full GLAD is taken as reference category.","nonInferiorityType":"OTHER","pValue":"<0.001","pValueComment":"For effect estimation, hazard ratios are reported with 95% confidence interval. The significance level is set to two-sided ≤ 5% (p ≤ 0.05).","paramType":"Hazard Ratio (HR)","paramValue":"4.49","statisticalComment":"The Model developed by Anderson and Gill (1982) is an extension to the proportional hazard model (Cox model) for time to recurrent event analysis.","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"1.98","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.21","groupDescription":"For the analysis of susceptibility to infection, the time to next infection was examined using the Andersen-Gill model. This model is an extension to the proportional hazard model (Cox model) for time to recurrent event analysis. The null hypothesis is that the GLAD-Score has no effect on susceptibility to infection.","groupIds":["OG000","OG001"],"nonInferiorityComment":"To estimate the relevance of guideline adherent treatment (GLAD) for the susceptibility to infection, full GLAD is taken as reference category.","nonInferiorityType":"OTHER","pValue":"<0.001","pValueComment":"For effect estimation, hazard ratios are reported with 95% confidence interval. The significance level is set to two-sided ≤ 5% (p ≤ 0.05).","paramType":"Hazard Ratio (HR)","paramValue":"2.52","statisticalComment":"The Model developed by Anderson and Gill (1982) is an extension to the proportional hazard model (Cox model) for time to recurrent event analysis.","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"221"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"889"},{"groupId":"OG001","value":"75"},{"groupId":"OG002","value":"122"}],"units":"Participants"}],"description":"For the analysis of susceptibility to infection, the time to next infection was examined using the Andersen-Gill model for recurrent events. For effect estimation, hazard ratios are reported with 95% confidence interval in each case. GLAD-Score 2 is Reference, a higher hazard ratio means a higher susceptibility to infection.","groups":[{"description":"2 points for full GLAD","id":"OG000","title":"GLAD-Score 2"},{"description":"1 point for deviations in dose or interval (+/- 10%) or a late start of IgRT (\\>28 days after a severe infection (≥ grade 3)","id":"OG001","title":"GLAD-Score 1"},{"description":"0 points for IgRT without indication (overuse) or omitted IgRT despite recommendation (underuse). Likewise, 0 points were awarded if both the dose and the interval deviated from the GL recommendations (e.g. underdosed single dose) or if IgRT was not started until more than 3 months after hypogammaglobulinemia and at least one severe infection","id":"OG002","title":"GLAD-Score 0"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Median study observation period of 18.2 months","title":"Guideline Adherence and Susceptibility to Infection","type":"SECONDARY","unitOfMeasure":"Number of infectious events"}